<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505231</url>
  </required_header>
  <id_info>
    <org_study_id>0352/08</org_study_id>
    <nct_id>NCT01505231</nct_id>
  </id_info>
  <brief_title>Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery</brief_title>
  <acronym>VaNCS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoplegic syndrome after cardiac surgery is a common complication after cardiac surgery,
      with negative impact on patient outcomes and hospital costs. Pathogenesis of vasodilatory
      phenomenon after cardiac surgery remains a matter of controversy. Loss of vascular tone can
      be partly explained by the depletion of neurohypophyseal arginine vasopressin stores. The
      investigators hypothesized that the use of arginine vasopressin would be more effective on
      treatment of shock after cardiac surgery than norepinephrine, decreasing the composite end
      point of mortality and severe morbidity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of major morbidity according to Society of Thoracic Surgery</measure>
    <time_frame>30 days</time_frame>
    <description>The primary end point is major morbidity according to STS (30-days mortality, mechanical ventilation &gt; 48 hours, mediastinitis, surgical reexploration, stroke, acute renal failure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic effects</measure>
    <time_frame>28 days</time_frame>
    <description>the time to attainment of hemodynamic stability ; the changes in hemodynamic variables; and the use of dobutamine or other inotropic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of adverse events and safety</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events were categorized as arrhythmias, myocardial necrosis, skin necrosis, ischemia in limbs or distal extremities, or secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Days on mechanical ventilation during 30-days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infecction</measure>
    <time_frame>30-days</time_frame>
    <description>Incidence of new infecction, sepsis, severe sepsis or septic shock in 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU and Hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Compare between groups the period of time (days) that patients were in ICU and in Hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasopressin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded vasopressin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement.</description>
    <arm_group_label>Vasopressin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement</description>
    <arm_group_label>Norepinephrine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  need vasopressor support

        Exclusion Criteria:

          -  younger than 18 years;

          -  surgery without cardiopulmonary bypass;

          -  emergency procedure;

          -  ascending and descending thoracic aortic procedures;

          -  left ventricular aneurysm resection; enrollment in another study;

          -  pregnancy;

          -  neoplasm;

          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;

          -  severe hyponatremia (Na&lt;130mEq/L);

          -  acute mesenteric ischemia;

          -  acute myocardial infarction;

          -  cardiogenic shock; and refusal to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ludhmila Hajjar, MD, PhD</last_name>
    <phone>55-11-93194401</phone>
    <email>ludhmila@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Coração</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludhmila Hajjar, MD, PhD</last_name>
      <phone>55-11-93194401</phone>
      <email>ludhmila@usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ludhmila Abrahão Hajjar</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Shock</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>vasopressin</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

